Advertisement
Advertisement
U.S. markets open in 5 hours 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.34-0.24 (-2.51%)
At close: 04:00PM EDT
9.25 -0.09 (-0.96%)
After hours: 06:04PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close9.58
Open9.73
Bid0.00 x 1800
Ask0.00 x 3200
Day's Range9.15 - 9.91
52 Week Range6.18 - 27.96
Volume2,705,709
Avg. Volume2,443,823
Market Cap1.474B
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-2.30
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IOVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Iovance Biotherapeutics, Inc.
    NKTR: What does Argus have to say about NKTR?NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

    STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company’s financial operations. “Ryan’s deep financial leadership experience will be instrument

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Conferences

    SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences in September: Wells Fargo Healthcare ConferenceFireside Chat: September 7 at 2:35 p.m. ETBoston, MA HC Wainwright Annual Global Investment ConferencePresentation: On demand beginning September 12 at 7:00 a.m. ETVirtual and Ne

  • GlobeNewswire

    Iovance Biotherapeutics to Present Posters at ESMO 2022

    SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the publication of abstracts reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, France, September 9 – 13, 2022. The details of the abstracts, which are available on Iovance.

Advertisement
Advertisement